In vitro and in vivo studies of isogenic PTEN (+/+) and PTEN (-/-) mouse cells as well as human cancer cells with defined PTEN status confirmed that the growth of PTEN null cells was blocked preferentially by pharmacologic FRAP/mTOR inhibition [370]. This evidence concerns the gene MTOR and cancer.